QUANTITATIVE ANALYSIS OF HIV-1 PROVIRAL DNA IN SAMPLES FROM PATIENTS WITH AIDS

一种快速、简便的前病毒DNA含量测定方法 人外周血单个核细胞 免疫缺陷病毒I型(HIV-1)感染是通过使用 聚合酶链式反应(PCR)技术。我们发现大多数人 T细胞中未分离的PBM中可检测到的HIV前病毒DNA拷贝数 B细胞/单核细胞含有较少的HIV DNA(93.9+- T细胞为3.5%，B细胞/单核细胞为6.1+-3.5%(P&lt；0.05)。当我们 13例艾滋病患者外周血中HIV前病毒DNA含量的比较 或在使用2‘，3’双脱氧肌苷抗逆转录病毒治疗前和期间的ARC (DDI)，在I期临床研究中作为递增剂量给予， 在12个可评估的患者中有9个观察到显著的下降。 服药8~14周(P&lt；0.02)。下降的幅度似乎更大 在接受相对较高剂量的药物的患者中明显。 这些数据表明，用聚合酶链式反应可定量检测外周血中的HIV病毒DNA。 可行，理论上可能有助于全面监测 接受实验性治疗的患者。然而，更大规模的研究将是 以确定该检测的敏感性和特异性，以及 进一步的纵向研究将是至关重要的。

A rapid and simple method for determining the proviral DNA content in peripheral blood mononuclear cells (PBM) from patients with human immunodeficiency virus type I (HIV-1) infection was established by using the polymerase chain reaction (PCR) technique. We found that the majority of HIV proviral DNA copies detectable in unfractionated PBM resided in T cells, while B cells/monocytes contained lesser amounts of HIV DNA (93.9+- 3.5% for T cells versus 6.1+-3.5% for B cells/monocytes: p<0.05). When we compared the amount of HIV proviral DNA in PBM from 13 patients with AIDS or ARC before and during antiretroviral therapy with 2',3'dideoxyinosine (ddI) which was given as an escalating dose in a phase I clinical study, a significant decrease was observed in 9 out of 12 evaluable patients receiving the drug for 8 to 14 weeks (p<0.02). The decrease appeared more pronounced in patients receiving relatively high doses of the drug. These data suggest that the quantitation of HIV viral DNA in PBM by PCR is feasible and may theoretically contribute to an overall monitoring of patients receiving experimental therapy. However, larger studies will be required to determine the sensitivity and specificity of this assay and further longitudinal studies will be essential.